Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Shigellosis | 0 | map05131 | albendazole | 6604200 | drug-path |
| Pathogenic Escherichia coli infection | R-HSA-9609646 | map05130 | albendazole | 6604200 | drug-path |
| Amyotrophic lateral sclerosis (ALS) | Q8NDH6-2 | 0 | albendazole | 6604200 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | albendazole | 6604200 | drug-path |
| Apoptosis | R-HSA-109581 | map04210 | albendazole | 6604200 | drug-path |
| Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | albendazole | 6604200 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | labetalol | 3869 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | labetalol | 3869 | drug-path |
| Circadian rhythm - mammal | R-HSA-400253 | 0 | labetalol | 3869 | drug-path |
| Cell cycle | R-HSA-1640170 | map04110 | labetalol | 3869 | drug-path |
| ECM-receptor interaction | R-HSA-373711 | map04512 | labetalol | 3869 | drug-path |
| Chemokine signaling pathway | R-HSA-168638 | map04062 | labetalol | 3869 | drug-path |
| Allograft rejection | R-HSA-9679028 | map05330 | labetalol | 3869 | drug-path |
| Type I diabetes mellitus | R-HSA-5683209 | map04940 | labetalol | 3869 | drug-path |
| Natural killer cell mediated cytotoxicity | R-HSA-5218921 | map04650 | labetalol | 3869 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | labetalol | 3869 | drug-path |
| Gap junction | R-HSA-190861 | map04540 | labetalol | 3869 | drug-path |
| Cytokine-cytokine receptor interaction | R-HSA-6788467 | map04060 | labetalol | 3869 | drug-path |
| Ribosome | R-HSA-5368277 | map03010 | labetalol | 3869 | drug-path |
| Alzheimer's disease | R-HSA-1643685 | 0 | oxybutynin | 4634 | drug-path |